Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys

Fig. 1

Plasma Aβ42/40 levels were increased following CS-6253 injection in the GLP study. The increase at 4 h and 48 h p.i. compared with 5 min p.i. on the day of injection were statistically significant (p < 0.001 for both). The values were shown as percent change from the first measurement point at 5 min p.i. on day 1. The measurements in the placebo arm were only done at 5 min and 48 h on days 1 and 25. The mixed-effects models for this measurement used only actively treated animals; fixed effects included indicator variables for treatment dose, injection number, and time of assessment (4 h and 48 h, each compared with the 5-min baseline timepoint). A random intercept of subject was specified to model correlated outcomes arising from repeated measurements

Back to article page